Lung Cancer Therapeutics Market: Targeted Therapy, Immunotherapy & Chemotherapy Trends 2025 | Pfizer, Merck & Co, Amgen, AstraZeneca.

The global lung cancer therapeutics market reached US$ 24.00 Billion in 2023, with a rise of US$ 25.92 Billion in 2024 and is expected to reach US$ 55.09 Billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033.

The Lung Cancer Therapeutics Market focuses on treatments for one of the most prevalent and fatal cancers worldwide. Therapies include targeted therapy, immunotherapy, chemotherapy, and emerging precision medicine approaches. Market growth is driven by increasing incidence, early diagnosis, and ongoing clinical research. Advances in biomarkers, liquid biopsy, and personalized treatment regimens improve patient outcomes. Pharmaceutical R&D pipelines are intensifying, leading to novel drug approvals. Growing awareness and supportive healthcare infrastructure further boost market adoption.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Lung Cancer Therapeutics Market Landscape:- https://datamintelligence.com/download-sample/lung-cancer-therapeutics-market?rk

☛ Lung Cancer Therapeutics Market Recent Developments 2025:

United States:

✅ In July 2025, AstraZeneca received FDA approval for a next-gen targeted therapy for EGFR-mutated lung cancer.

✅ In June 2025, Pfizer expanded clinical trials for a combination immunotherapy in non-small cell lung cancer.

Japan:

✅ In August 2025, Chugai Pharmaceutical initiated clinical studies of antibody-drug conjugates for lung cancer treatment.

✅ In May 2025, Takeda launched a research program for next-generation targeted therapies in lung cancer patients.

☛ Lung Cancer Therapeutics Market Competitve Landscape:

Pfizer, Merck & Co, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis AG, Eli Lilly, F. Hoffmann-La Roche Ltd and Abbvie.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/lung-cancer-therapeutics-market

☛ Segment Covered in the Lung Cancer Therapeutics Market:

By Treatment: Targeted Therapy, Immunotherapy, Chemotherapy, Radiation Therapy, Others.

By Disease Type: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC).

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other.

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live Lung Cancer Therapeutics Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=lung-cancer-therapeutics-market

☛ Regional Analysis for Lung Cancer Therapeutics Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

☛ FAQ's

Q1: What is the current size of the Lung Cancer Therapeutics Market and its future potential?

A: The global lung cancer therapeutics market reached US$ 24.00 Billion in 2023, with a rise of US$ 25.92 Billion in 2024 and is expected to reach US$ 55.09 Billion by 2033

Q2: How fast is the Lung Cancer Therapeutics Market expected to grow in the coming years?

A: The market is forecast to expand at a robust CAGR of 8.8% between 2025 and 2032, signaling strong global growth and investment potential.

Q3: Which regions are dominating the Lung Cancer Therapeutics Market and which are fastest-growing?

A: North America dominating the Lung Cancer Therapeutics Market.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.